Cancer Research and Treatment

Original Article

Metabolic Burden Measured by ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Is a Prognostic Factor in Patients with Small Cell Lung Cancer: Mi-Hyun Kim, Ji Seok Lee, Jeong Ha Mok, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Seong-Jang Kim, Min Ki Lee; Cancer Res Treat. 2014;46(2):165-171. Published online April 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.2.165

Purpose

Evidence regarding the usefulness of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) in predicting the prognosis of non-small cell lung cancer is increasing. However, data on small cell lung cancer (SCLC) are scarce. The aim of this study was to evaluate the prognostic value of metabolic parameters measured using ¹⁸F-FDG PET/CT in patients with SCLC.

Materials and Methods

We conducted a retrospective review of 114 patients with pathologically proven SCLC (26 cases of limited disease and 88 cases of extensive disease) who underwent pretreatment ¹⁸F-FDG PET/CT. The maximal SUV (SUV_max) was used quantitatively for determination of FDG PET activity. The SUV_max of the primary tumor (primary SUV_max), the sum of SUV_max values of malignant lesions (SUV_sum), and the mean SUV_max of malignant lesions were calculated.

Results

The patient population was subdivided using a median SUV_sum value of 24.6. High SUV_sum showed a significant association with known factors for poor prognosis, including higher neuron-specific enolase (p=0.010), CYFRA 21-1 (p=0.014), and extensive disease status (p=0.007). Patients with high SUV_sum had significantly shorter median overall survival (6.6 months vs. 13.0 months, p<0.001) and progression-free survival (5.2 months vs. 8.0 months, p<0.001) than patients with low SUV_sum. Results of multivariate analysis showed that SUV_sum, chemotherapy cycles, and the response to first-line treatment were significant prognostic factors of survival. In contrast, mean SUV_max and primary SUV_max were not significant predictors of survival.

Conclusion

In this study, metabolic burden represented by SUV_sum from pretreatment ¹⁸F-FDG PET/CT was an independent prognostic factor in patients with SCLC.

Citations

Citations to this article as recorded by

Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer
Mine ARAZ, Cigdem SOYDAL, Elgin ÖZKAN, Elif SEN, Demet NAK, Ozlem N. KUCUK, Ugur GÖNÜLLÜ, K. Metin KIR
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2022;[Epub] CrossRef
Predictive Factors of Complete Tumor Response to First Line Chemotherapy in Patients with Extensive-stage Small Cell Lung Cancer
Eyyüp Çavdar, Yakup İriağaç, Abdullah Sakin, Erdoğan Selçuk Şeber
Bagcilar Medical Bulletin.2022; 7(2): 130. CrossRef
Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature
Tine Nøhr Christensen, Per Kragh Andersen, Seppo W. Langer, Barbara Malene Bjerregaard Fischer
Diagnostics.2021; 11(2): 174. CrossRef
Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC)
Cem Mirili, Isa Burak Guney, Semra Paydas, Gulsah Seydaoglu, Tuba Korkmaz Kapukaya, Ali Ogul, Serkan Gokcay, Mahmut Buyuksimsek, Abdullah Evren Yetisir, Bilgin Karaalioglu, Mert Tohumcuoglu
International Journal of Clinical Oncology.2019; 24(2): 168. CrossRef
Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer
Xiaozhou Yu, Yanjia Zhu, Jian Wang, Xiuyu Song, Lei Zhu, Xiaoyuan Men, Xiaofeng Li, Dong Dai, Wengui Xu
Nuclear Medicine Communications.2017; 38(2): 193. CrossRef
Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer
Meryem Aktan, Mehmet Koc, Gul Kanyilmaz, Berrin Benli Yavuz
Annals of Nuclear Medicine.2017; 31(6): 462. CrossRef
The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer
Soo Hyun Kwon, Seung Hyup Hyun, Joon-Kee Yoon, Young-Sil An, Young-Taek Oh, Jin-Hyuck Choi, Kwang Joo Park, Su Jin Lee
Medicine.2016; 95(5): e2772. CrossRef
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik, L.J. Appleman, A.W. Tolcher, K.P. Papadopoulos, M. Beeram, D.W. Rasco, G.J. Weiss, J.C. Sachdev, M. Chadha, M. Fulk, S. Ejadi, J.M. Mountz, M.T. Lotze, F.G.S. Toledo, E. Chu, M. Jeffers, C. Peña, C. Xia, S. Reif, I. Genvresse, R.K. Ramanathan
Annals of Oncology.2016; 27(10): 1928. CrossRef
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
Alberto A. Chiappori, Gregory A. Otterson, Afshin Dowlati, Anne M. Traynor, Leora Horn, Taofeek K. Owonikoko, Helen J. Ross, Christine L. Hann, Taher Abu Hejleh, Jorge Nieva, Xiuhua Zhao, Michael Schell, Daniel M. Sullivan
The Oncologist.2016; 21(10): 1163. CrossRef
Deriving global quantitative tumor response parameters from 18F-FDG PET-CT scans in patients with non-Hodgkin’s lymphoma
Frederic Sampedro, Anna Domenech, Sergio Escalera, Ignasi Carrió
Nuclear Medicine Communications.2015; 36(4): 328. CrossRef
Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
Si Shi, Shunrong Ji, Yi Qin, Jin Xu, Bo Zhang, Wenyan Xu, Jiang Liu, Jiang Long, Chen Liu, Liang Liu, Quanxing Ni, Xianjun Yu
Cancer Letters.2015; 360(2): 227. CrossRef
Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery
Sung Hwan Kim, Jong Hoon Lee, Guk Jin Lee, Songmi Jeong, Yoo-Kang Kwak, Hoon-Kyo Kim, Deog Gon Cho, Young Ha Park, Mina Yu, Sei Chul Yoon
Medicine.2015; 94(24): e955. CrossRef
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival
Elba C. Etchebehere, John C. Araujo, Patricia S. Fox, Nancy M. Swanston, Homer A. Macapinlac, Eric M. Rohren
Journal of Nuclear Medicine.2015; 56(8): 1177. CrossRef
Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT
Eric M. Rohren, Elba C. Etchebehere, John C. Araujo, Brian P. Hobbs, Nancy M. Swanston, Michael Everding, Tracy Moody, Homer A. Macapinlac
Journal of Nuclear Medicine.2015; 56(10): 1507. CrossRef

11,943 View
67 Download
16 Web of Science
14 Crossref

First
Prev
Page of 1
Next
Last

Search